A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
Doctors are doing a study to test if a new medicine called ruxolitinib, combined with other medicines, can help people with a blood cancer called multiple myeloma who are getting worse. They want to see if the medicine is safe and if it works well.
Doctors are doing a study to test if a new medicine called ruxolitinib, combined with other medicines, can help people with a blood cancer called multiple myeloma who are getting worse. They want to see if the medicine is safe and if it works well.
Third Opinion AI Generated Synopsis
Trial Summary
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
